Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD
- PMID: 37614206
- DOI: 10.1002/ana.26768
Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD
Comment on
-
NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.Ann Neurol. 2023 Oct;94(4):620-631. doi: 10.1002/ana.26725. Epub 2023 Jul 25. Ann Neurol. 2023. PMID: 37345460 Free PMC article.
References
-
- Buchave P, Minthon L, Zetterberg H, et al. Cerebrospinal fluid levels of β-amyloid 1-42 but not tau are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012;69:98-106.
-
- Van Harten AC, Wiste HJ, Weigand SD, et al. Detection of Alzheimer's disease amyloid beta 1-42, p-tau and t-tau assays. Alz Dementia 2022;18:635-644.
-
- Kaplow J, Vandijck M, Gray J, et al. Concordance of Lumipulse cerebrospinal fluid t-tau/A42 ratio with amyloid PET status. Alz Dementia 2020;16:144-152.
-
- Tosun D, Demir Z, Veitch DP, et al. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's Dementia 2022;18:1370-1382.
-
- Masliah E, Mallory M, Alford M, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001;56:127-129.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases